Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Current articles 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Acta Virologica Vol.58, No.4, p.301-308, 2014 |
||
Title: Targeting microRNA-122: Walking on cutting edge of hepatitis C virus infection therapy | ||
Author: M. MOTAVAF, S. SAFARI, S. M. ALAVIAN | ||
Abstract: Hepatitis C virus (HCV) infection, with an estimated 170 million carriers worldwide, remains a major cause of chronic liver disease. Current anti-HCV treatments have significant side effects and have met with only partial success. Therefore, a more effective therapeutic modality for HCV infection is needed. The stability and propagation of HCV is dependent on the interaction between its genome and a highly abundant liver microRNA (miRNA), known as microRNA-122 (miR-122). As a conserved host factor that would not be expected to evolve resistance mutations, miR-122 makes an attractive antiviral target. In this review we will discuss how targeting miR-122, using antisense oligonucleotides (ASOs), can be a new anti-HCV treatment. |
||
Keywords: hepatitis C virus; microRNA; locked nucleic acid therapy; microRNA-122; human | ||
Year: 2014, Volume: 58, Issue: 4 | Page From: 301, Page To: 308 | |
doi:10.4149/av_2014_04_301 |
||
|
![]() |
|